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In the past three decades, not much has changed in
the pathophysiologic concepts of dermatomyositis and
polymyositis. However, in the past couple of years,
many changes have occurred reﬂecting the extremely
complex nature of the immune response in general.
New pathophysiologic models are needed, but at pres-
ent, none of them encompasses all the recent ﬁndings.
The changing concepts of dermatomyositis and poly-
myositis offer new opportunities for unraveling these
diseases and developing better strategies for prevention 
and treatment. This article discusses the most important
developments and their methodologic short-comings.
Introduction
Idiopathic inflammatory myopathy (IIM) is a group of 
systemic diseases characterized by acquired muscle weak-
ness and the presence of inflammatory infiltrates in skeletal
muscle tissue. The three main diseases within this group are
dermatomyositis (DM), polymyositis (PM), and sporadic
inclusion body myositis (s-IBM). DM and PM are regarded
to be autoimmune diseases, whereas the immune response in 
s-IBM is thought to be secondary to degenerative changes.
This review focuses on the immunopathophysiology of DM
and PM and only mentions s-IBM sporadically. 
Simplicity of the Past
Until recently, IIM was not very difficult to understand.
The landmark review articles by Bohan and Peter [1,2] 
clearly show the existence of two different forms of IIM:
DM and PM. The major difference between the two is that 
the former is characterized by a typical rash, and the latter 
is not. Not much had changed by the time the next major 
review article was written by Dalakas [3]. The major dif-
ference was that a subgroup of patients with PM turned 
out to have a different myopathy: s-IBM. Over time, it
became clear that s-IBM differs from PM and DM, clini-
cally, histologically, and pathophysiologically. The most
recent major clinical review article on the subject does not
add many changes to this view of IIM [4].
Also pathologically, the field of IIM was rather simple. 
DM was though to be a humorally mediated autoimmune
disease in which the immune process is mainly directed
against the intramuscular microvasculature [3]. On the
other hand, PM and s-IBM were regarded as diseases 
characterized by an antigen-directed cytotoxic immune
response mediated by cytotoxic T cells [3].
All in all, this view was rather simple. There are three 
diseases: DM, PM, and s-IBM. DM is a humorally medi-
ated angiopathy, PM is the result of a cytotoxic immune
response directed against the myofibers, and s-IBM has
some features of PM but is mainly characterized by
Alzheimer-like degenerative changes.
A bulk of convincing evidence supports these pathophys-
iologic models. The earliest histologic change in DM is the
deposition of C3b, C4b, and the membrane attack complex
on the intramuscular capillaries [5]. This complement activa-
tion is thought to be induced by antibodies directed against
the endothelial cells. This activation subsequently leads to 
swelling and vacuolization of the endothelial cells, capillary 
necrosis, and perivascular inflammation. These perivascular
inflammatory infiltrates mainly consist of B cells and CD4+
T cells, thus reflecting the humoral nature of the immune
response. As a result of the capillary damage, reflected his-
tologically by a clear reduction of the number of capillaries,
ischemia and eventually destruction of muscle fibers occur.
As a result of this process, the typical histologic feature of 
perifascicular atrophy develops, caused by the hypoperfu-
sion of the perifascicular regions.
Widespread expression of major histocompatibility
complex (MHC) class I molecules on the sarcolemma is one
of the earliest features of PM. Subsequently, autoinvasive
Immunopathophysiology of the Idiopathic Inflammatory Myopathies Hengstman 281
CD8+ T cells invade non-necrotic muscle fibers. A subset
of these autoinvasive CD8+ cells are clonally expanded,
indicating that the immune response is driven by certain 
antigens, presumed to be present in the muscle tissue.
But nature, and thus disease processes, are extremely
complex. The conceptual difference between inflam-
matory processes and noninflammatory processes are
arbitrary. Where does the inflammation end, and where
does degeneration, necrosis, or apoptosis begin? Humoral
and cellular immune mechanisms work in close harmony
with each other and are usually intertwined. Proteins
including cytokines and chemokines never have just one
activity. Their activity depends on the complex cellular 
environment, and degradation or modification of proteins 
renders completely different functions. Especially in the 
past few years, the story of IIM has been shown to be
more complex than it had once appeared. 
Common Problems in Pathophysiology 
Studies of IIM
One of the main problems haunting research in IIM is the 
lack of clear internationally accepted and tested diagnos-
tic criteria, especially for PM. Some authors have stated
that PM does not exist, whereas others still use the Bohan
and Peter criteria [1,2], resulting in many patients being
diagnosed with PM. 
DM and especially PM are very inhomogeneous groups
of diseases. Sometimes they are associated with other 
inflammatory connective tissue diseases or with cancer. 
Very specific autoantibodies can be found in some patients, 
and they have been shown to define very distinct clinical
syndromes including typical pathologic abnormalities. It is
not unlikely that the pathophysiology in all of these cases 
differs from each other to some extent. Yet, most studies
do not take these differences into account, and they lump 
all cases together under the heading PM or DM.
Another methodologic problem is that most studies do
not use appropriate control groups. Most studies have two
or three diagnostic groups (DM, PM, and s-IBM) and com-
pare these to each other and to a control group of normal
subjects. Only rarely is a non-IIM myopathy control group 
used. The most ideal control group would consist of patients 
with a non-IIM myopathy with known inflammation in
muscle tissue (eg, facioscapulohumeral muscular dystrophy
and dysferlinopathies). Most of the studies discussed in this 
review article used normal controls. Thus, the reported find-
ings could possibly be common in many myopathies, and
may at least in theory, have nothing to do with the immuno-
pathophysiology typical for DM or PM. 
Changes in Pathophysiologic Concepts
Perifascicular atrophy is not caused by hypoperfusion
The perifascicular atrophy in DM is thought to be due to 
ischemia, as stated earlier. Recently, though, this concept 
has been challenged [6]. Perifascicular atrophy is not seen
in models of ischemic myopathy [7]. Instead of the perifas-
cicular regions, the central portion of the fascicles appears
to be most vulnerable, whereas the perifascicular regions
are spared [7]. In the recent study by Greenberg et al. [8•], 
it is shown that MxA, an interferon (IFN)-B–inducible 
protein, is strongly expressed in regions of perifascicular
atrophy and also in normal-appearing perifascicular fiber.
MxA was also expressed in the capillaries. MxA has not
been reported to be upregulated in ischemic tissue. The
expression of MxA on both capillaries and perifascicular
muscle fibers suggests that a common mechanism produces
these abnormalities in both locations, rather than the capil-
lary abnormalities causing the perifascicular atrophy. 
Interferon-induced ELR-negative CXC chemokines 
may cause the vasculopathy in DM
Inflammation is characterized by marked changes in blood
vessel volume. Many chemokines and cytokines exert direct
angiostatic and angiogenic effects on endothelial cells, and
modulate the expression of angiogenic growth factors such
as angiopoietin 1 and vascular endothelial growth factor.
Examples of these cytokines include tumor necrosis factor–
B, interleukin-1, IFN-H, and IFN-B. Several CXC chemokine
family members are important regulators of angiogenesis [9].
CXC chemokines containing the ELR motif (three–amino
acid sequence Glu-Leu-Arg) are angiogenic, whereas CXC
chemokines lacking this motif are angiostatic. Fall et al.
[10•] studied the relationship between vasculopathy and 
the balance between ELR-positive and ELR-negative CXC 
chemokines in muscle biopsies from seven patients with
juvenile DM and from seven healthy controls. They found 
that the angiostatic ELR-negative CXC chemokines were
expressed at high levels, whereas the angiogenic ELR-posi-
tive CXC chemokines were barely detectable. The expression
of ELR-negative CXC chemokines in the juvenile DM muscle
biopsies correlated strongly with the intensity of the mono-
nuclear cell infiltration and with the degree of capillary
loss. Thus, it appears that IFN-induced ELR-negative CXC
chemokines contribute to a local atrophying effect in the
muscle’s vasculature through a receptor-mediated process. 
Unfortunately, the authors did not study muscle biop-
sies from patients with PM and non–immune-mediated 
myopathies. Therefore, the exact role of ELR-negative 
CXC chemokines in myositis is not known, but the study
does indicate that the balance between certain chemo-
kines may play a fundamental role.
Immature dendritic cells are recruited and mature
focally in DM and PM
Dendritic cells (DCs) play a key role in the development 
of the innate and adaptive immune responses. Two
main classes of DCs are recognized: myeloid DCs and
plasmacytoid DCs [11]. Myeloid DCs are potent anti-
gen-presenting cells that stimulate the adaptive immune 
response. Plasmacytoid DCs are capable of producing
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large amounts of IFN-B and IFN-C and are important 
in the innate immune system.
Most studies on IIM have focused on the adaptive
immune system, humoral in DM and cellular in PM. In
recent years though, it has been shown that there is a con-
siderable innate immune response in both DM and PM.
Page et al. [12•] showed that immature DCs are present
in the inflammatory infiltrates in DM and PM, and that
maturation of these DCs appears to occur in the inflamed
muscle tissue. Immunohistochemical techniques were used
on muscle biopsy specimens from six patients with DM,
six patients with PM, and five normal controls. Patients
were diagnosed according to the Bohan and Peter criteria
[1,2]. DCs were not seen in normal muscle tissue, but they 
were observed in four of six DM patients and in three of 
six PM patients. In DM, both mature and immature DCs
were mainly seen in the perivascular infiltrates, whereas
in PM, they were observed in the inflammatory infiltrates
surrounding muscle fibers.
The chemokine CCL20 and its receptor CCR6 are
critical for the recruitment of immature DCs [13,14]. Both
CCL20 and CCR6 were present in the inflammatory infil-
trates in DM and PM, in close association with immature
DCs [12•]. The chemokines CCL19 and CCL21 and their
receptor CCR7 are involved in the attraction of mature
DCs [15]. CCL19, CCL21, and CCR7 were not seen in
the muscle biopsies of DM and PM patients, thus indicat-
ing that the immature DCs that are actively attracted to
the inflamed muscle tissue mature locally. 
Based on their findings, the authors presented a model
in which, in response to local inflammation and the pro-
duction of proinflammatory cytokines, immature DCs are
attracted to muscle tissue in response to local CCL20 pro-
duction in perivascular infiltrates. The contribution of the
cytokine microenvironment leads to the differentiation 
to mature DCs, which can interact with T cells and thus 
cause a further recruitment of immature DCs. 
The authors did not find any clear differences between
DM and PM, indicating that their findings are not dis-
ease specific but apparently part of the general immune 
response seen in IIM. Unfortunately, they did not study 
non-IIM myopathies. DCs were not observed in all IIM
muscle biopsies studied. Two DM patients did not show 
any evidence of mature or immature DCs, as did two
PM patients. One PM patient only showed the presence 
of mature DCs. Apparently, attraction of immature DCs
and focal maturation of these cells does not occur in every 
patient or in every stage of the disease.
The majority of CD4+ cells in DM are plasmacytoid
dendritic cells and not T cells
As stated earlier, CD4+ cells are present in the perivascular
infiltrates in muscle biopsies of patients with DM. These 
cells are usually thought to be T-helper cells, as would be 
expected in a humorally mediated immune response [16].
Greenberg et al. [8•] demonstrated that most of these 
CD4+ cells are not CD3+, and thus not T-helper cells. In
fact, most of the CD4+ cells in DM are plasmacytoid DCs.
Plasmacytoid DCs secrete IFN-B [17], and in the same 
study it is shown that IFN-B and IFN-C play an impor-
tant role in DM. Furthermore, the authors found that 
these CD4+ cells are not mainly located in the perivascular 
regions. Most cells were in fact located in the endomysium
and perimysium.
Dendritic cells in PM and s-IBM function focally as
antigen-presenting cells
DCs were studied in PM and s-IBM using immunohisto-
chemical techniques [18•]. The BDCA-2 marker was used to 
identify plasmacytoid DCs and BDCA-1 for myeloid DCs.
Because BDCA-1 can also be expressed by a small group
of B cells, CD19 immunohistochemistry was performed to 
differentiate between myeloid DCs and B cells. Investiga-
tors studied muscle biopsies from 20 patients with s-IBM, 
10 with PM, 15 with DM, and five normal controls.
Myeloid DCs were found in almost all patients with 
PM and s-IBM. They were usually seen as widely dis-
tributed cells across the section with additional focal
accumulations. These accumulations were typically 
endomysial and either surrounded myofibers, sometimes 
invading non-necrotic muscle fibers, or appeared as dense
collections between myofibers. The accumulations of DCs
in PM and s-IBM mainly consisted of myeloid DCs rather
than plasmacytoid DCs. In DM on the other hand, most
DCs were plasmacytoid, as stated earlier [8•].
The clear presence of large amounts of myeloid DCs in 
muscle tissue from patients with PM and s-IBM suggests a
crucial role of these cells in the immune response in these
diseases. One of the hypotheses raised by the authors is
that these myeloid DCs function as antigen-presenting
cells in the inflamed muscle tissue and that they activate
T cells locally.
An antigen-driven humoral immune response is 
present in PM and s-IBM
PM and s-IBM are characterized by a CD8+ T-cell–medi-
ated immune response directed against MHC class I
expressing non-necrotic muscle fibers, as stated earlier.
Evidence that autoreactive T cells play an important role 
in these two diseases is very convincing: a restricted T-cell
receptor repertoire is found in muscle biopsies of PM and 
s-IBM patients [19–21], an oligoclonal expansion of muscle-
infiltrating T cells is present in both diseases [22–25], and a 
long-term presence of clonally expanded T cells is found in
these two subtypes of IIM [26–28]. B cells are sparse in the
inflammatory infiltrates in PM, and it is unknown whether 
they are involved in the disease process.
It has long since been recognized that some patients 
with PM have specific autoantibodies, indicating a role
for a humoral autoimmune response to some extent [29].
More recent studies of muscle messenger RNA expression
have shown an abundance of immunoglobulin tran-
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scripts in PM and s-IBM [30,31] and the presence of large
numbers of CD138+ plasma cells [31], providing further
evidence for a humorally mediated immune response in
PM and s-IBM.
In a recent study, Bradshaw et al. [32•] studied the 
molecular characteristics of the H chain portion of the
Ag receptor. Muscle biopsies from patients with DM, 
PM, and s-IBM, and those from normal controls were 
studied. Analysis of the sequences of the variable region
gene revealed clear evidence of affinity maturation based 
on the detection of significant somatic mutation, isotype
switching, receptor revision, codon insertion/deletion, and
oligoclonal expansion within the B- and plasma cell popu-
lations [32•]. These findings were present for all forms of 
IIM studied but were absent in the normal controls.
Analysis of tissue regions isolated by laser capture 
microdissection showed clonal expansion and variation,
indicating that local B-cell maturation occurs in inflamed 
muscle tissue. Laser capture microdissection was only
performed on one patient with DM, one with PM, and 
one with s-IBM. Clonal expansion was not observed in
the muscle biopsy specimen from the patient with PM.
Nevertheless, based on these findings, it can be 
concluded that antigens drive a B-cell antigen-specific
response in muscle in patients with DM, PM, and s-IBM.
The only shortcoming of the study is that researchers used 
normal controls and not non-IIM myopathies as a control
group. Theoretically, it is possible that a B-cell antigen-
specific immune response can be found in myopathies in
general. Furthermore, they did not specify the diagnos-
tic criteria they used. All in all, this study does indicate
convincingly that an antigen-driven humorally mediated 
immune response is present in all three subgroups of IIM.
Myositis antigens are expressed in immature regener-
ating muscle fibers and in cancer tissue
Myositis-specific autoantibodies (MSAs) are present in
a subgroup of patients with IIM. These antibodies are
directed against proteins involved in the process of protein
synthesis and RNA translation [33]. One of the mysteries
surrounding these disease-specific autoantibodies is the
fact that they are directed against ubiquitously expressed
proteins. An elegant study by Casciola-Rosen et al. [34••] 
showed that the expression of these antigens was low in
normal muscle tissue but increased several-fold in myosi-
tis muscle tissue. Immunohistochemical analysis showed 
that the highest level of antigen expression was present
in regenerating muscle cells. Furthermore, in an ex-vivo 
model of muscle differentiation, myositis-specific antigens
were expressed at highest levels in immature myoblasts,
and expression levels decreased as myotube development
ensued. Based on these findings, it was concluded that
damaged regenerating muscle tissue rather than normal
muscle tissue provides the source of MSA development.
The link between myositis and cancer has been noted 
for a long time. In the same study mentioned above, it
was shown that myositis-specific antigen expression does
not only occur in muscle tissue in myositis but can also
be found in some forms of cancer known to be associ-
ated with myositis [34••]. Based on these findings, the
authors proposed a model for the development of cancer-
associated myositis. Myositis-specific antigen expression
in a tumor leads to a specific immune response directed
against the tumor. In most cases, this immune response
effectively controls or eliminates the tumor. In a subset
of patients, subsequent muscle damage from a variety of 
potential causes (eg, infection, toxins) leads to muscle
regeneration and expression of myositis-specific antigens,
which can then reactivate immune responses generated 
initially in the antitumor response [34••].
More than inflammation alone: the endoplasmic 
reticulum stress response and physical demand
The inflammation observed in muscle tissue is frequently
seen as the primary cause of the clinical syndrome of 
acquired muscle weakness in IIM; however, in the recent
years, it has become very clear that this is not true. The
degree of inflammation does not consistently correlate
with the severity of structural changes in muscle tissue or
the degree of clinical muscle weakness [35–38]. Several
findings have suggested that expression of MHC class
I antigens on the sarcolemma may potentially mediate
muscle fiber damage and dysfunction in the absence of 
lymphocytes [37,39–44]. A potential link between MHC
class I upregulation and the occurrence of muscle fiber 
damage and dysfunction in IIM may be the endoplasmic
reticulum (ER) stress response. The ER stress response is
caused by an imbalance between the load of proteins in the 
ER and the cell’s ability to process that load. Due to this 
imbalance, several signaling pathways are activated and
lead to adaptations within the cell. The ER stress response
can be activated by many pathologic conditions, including
viral infections, mutations, and ischemia [45,46]. 
Muscle biopsy specimens of five patients with PM,
five patients with DM, and four healthy controls were
studied. It was shown that two major components of the
ER stress response were highly activated [47•]. Subse-
quently, it was shown that overexpression of MHC class
I induces an ER stress response in a mouse model [47•].
One of the ER stress response pathways is the upregula-
tion of nuclear factor (NF)-LB (ER overload response), 
which is strongly activated in myositis [47•]. 
Based on their findings, the authors presented a model
in which the ER stress response plays an important role
in the pathophysiology of IIM. MHC class I expression in
muscle fibers initiates two ER stress response pathways:
ER overload response and unfolded protein response. The
ER overload response activates NF-LB, which will induce
NF-LB target genes including MHC class I upregulation,
thus initiating a self-sustained loop. NF-LB is known to 
suppress myoblast differentiation and to induce proin-
flammatory cytokine expression, thus causing muscle fiber
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damage [48]. This model is attractive, because it shows
that there is more to the immunopathophysiology than
inflammation alone. But the model mainly consists of 
speculations. The authors have shown that two ER stress
response pathways are activated in IIM, but this may be
the case in many different nonimmune myopathies as well. 
Furthermore, there is no proof that the ER stress response
truly results in muscle damage and dysfunction. 
MHC class-I expression plays an important role in
the theory above. Dorph et al. [49] studied the pres-
ence of inflammatory infiltrates, T cells, macrophages,
expression of MHC class I and class II antigens, and
IL-1B immunohistochemically in eight patients with
PM, three patients with DM, and six healthy controls. 
They did this not only in weak affected muscles but also 
in asymptomatic muscles. No difference was observed 
qualitatively or quantitatively for any of the variables 
studied. The authors concluded that other factors are 
required to produce clinical symptoms, one of which
may be physical demand.
Conclusions
During the past three decades not much has changed in
the pathophysiologic concepts of DM and PM, as can be
observed by reading the most important review articles
on the subject over the years [1–4]. However, in the
past couple of years, many changes have occurred in the
pathophysiologic models reflecting the extremely complex
nature of the immune response in general. This increasing
insight will hopefully result in better therapeutic strate-
gies, but it should be remembered that selective inhibition
or stimulation of certain pathways will inevitably result
in unexpected side effects, indicating once again that it is
not as simple as it appears.
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